The estimated Net Worth of Laboratories, Inc. Center is at least $3.78 million dollars as of 20 May 2020. Laboratories Center owns over 1,294,260 units of Windtree Therapeutics stock worth over $3,779,218 and over the last 4 years Laboratories sold WINT stock worth over $0.
Laboratories has made over 1 trades of the Windtree Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Laboratories bought 1,294,260 units of WINT stock worth $2,381,438 on 20 May 2020.
The largest trade Laboratories's ever made was buying 1,294,260 units of Windtree Therapeutics stock on 20 May 2020 worth over $2,381,438. On average, Laboratories trades about 1,294,260 units every 0 days since 2020. As of 20 May 2020 Laboratories still owns at least 1,239,088 units of Windtree Therapeutics stock.
You can see the complete history of Laboratories Center stock trades at the bottom of the page.
Laboratories's mailing address filed with the SEC is 7TH FL., NO.3-2, PARK ST.,, NANGANG DIST., TAIPEI CITY, F5, 11503.
Over the last 6 years, insiders at Windtree Therapeutics have traded over $1,982,541 worth of Windtree Therapeutics stock and bought 6,849,036 units worth $20,224,921 . The most active insiders traders include James Huang, Pharmaceutical Holdings Ltd... et Ii Investments Ltd Lph. On average, Windtree Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $425,323. The most recent stock trade was executed by Craig Fraser on 27 September 2023, trading 2,500 units of WINT stock currently worth $2,550.
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Windtree Therapeutics executives and other stock owners filed with the SEC include: